- Home
- PBHC vs ATOS Comparison
PBHC vs ATOS Comparison
Compare PBHC & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBHC
- ATOS
- Stock Information
- Founded
- PBHC 1859
- ATOS 2009
- Country
- PBHC United States
- ATOS United States
- Employees
- PBHC N/A
- ATOS N/A
- Industry
- PBHC Major Banks
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- PBHC Finance
- ATOS Health Care
- Exchange
- PBHC Nasdaq
- ATOS Nasdaq
- Market Cap
- PBHC 108.9M
- ATOS 114.5M
- IPO Year
- PBHC N/A
- ATOS 2012
- Fundamental
- Price
- PBHC $17.24
- ATOS $0.80
- Analyst Decision
- PBHC
- ATOS Strong Buy
- Analyst Count
- PBHC 0
- ATOS 3
- Target Price
- PBHC N/A
- ATOS $7.00
- AVG Volume (30 Days)
- PBHC 6.2K
- ATOS 678.1K
- Earning Date
- PBHC 01-31-2025
- ATOS 03-31-2025
- Dividend Yield
- PBHC 2.32%
- ATOS N/A
- EPS Growth
- PBHC N/A
- ATOS N/A
- EPS
- PBHC 0.62
- ATOS N/A
- Revenue
- PBHC $40,020,000.00
- ATOS N/A
- Revenue This Year
- PBHC N/A
- ATOS N/A
- Revenue Next Year
- PBHC N/A
- ATOS N/A
- P/E Ratio
- PBHC $27.94
- ATOS N/A
- Revenue Growth
- PBHC N/A
- ATOS N/A
- 52 Week Low
- PBHC $11.41
- ATOS $0.72
- 52 Week High
- PBHC $19.86
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- PBHC 55.65
- ATOS 41.00
- Support Level
- PBHC $17.00
- ATOS $0.79
- Resistance Level
- PBHC $17.26
- ATOS $0.89
- Average True Range (ATR)
- PBHC 0.20
- ATOS 0.05
- MACD
- PBHC 0.03
- ATOS 0.01
- Stochastic Oscillator
- PBHC 68.29
- ATOS 25.14
About PBHC Pathfinder Bancorp Inc. (MD)
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.